FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP

OMB APPE	ROVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA VRTX								(Chec	5. Relationship of Reporting Pe Check all applicable) X Director			on(s) to Issu			
INCORF	RTEX PHA PORATED	First) RMACEUTICA	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2009							X	X Officer (give title Other (specify below) CEO						
(Street) CAMBR (City)		MA State)	02139 (Zip)		4. If An	nendment,	Date o	of Original	Filed	(Month/Day	y/Year)		6. Ind Line) X	Form fil	ed by One	Repor	(Check Appl ting Person One Reporti	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date		2. Transa Date (Month/D	Execution Date,		e, Transaction Disposed Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct III Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) or (D)		се	Transaction(s) (Instr. 3 and 4)				1150.4)	
Common	Stock			02/05/	2009			A		47,201	(1) A	\$	0.01	1,142	2,245		D	
Common	Stock													12,4	145		I 4	101(k)
Common	Stock													207,	500			Shares in rust. ⁽²⁾
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
		3A. Deemed Execution Da if any (Month/Day/Y	Cod	saction e (Instr.	Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	e s ully g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	e V	(A)	(D)	Date Exercisab		Expiration Date	Title	Amou or Numb of Sha	er		Transaction(s) (Instr. 4)			
Stock Option	\$33.55	02/05/2009		A		236,000	П	05/05/2009	(3)	02/04/2019	Common Stock	236,	000	\$0	236,00	00	D	

Explanation of Responses:

- 1. Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir.
- $2.\ Shares\ held\ in\ trust\ for\ Dr.\ Boger's\ children.\ Dr.\ Boger\ disclaims\ beneficial\ ownership\ of\ such\ shares.$
- 3. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09.

Remarks:

<u>Valerie L. Andrews, Attorney-</u> <u>In-Fact</u>

02/06/2009

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.